Definium Therapeutics Inc. Common Shares vs Herbalife Nutrition Ltd — how do they compare? Definium Therapeutics Inc. Common Shares trades at $37.05 (market cap $4.59B), while Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 3.4× Herbalife Nutrition Ltd's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Herbalife Nutrition Ltd for 43 Days on average.
| DFTX | HLF | |
|---|---|---|
Market Cap | $4.59B | $1.34B |
Volume | 2,103,937 | 1,589,457 |
Sector | Health | Consumer Staples |
52-Week High | $48.45 | $19.96 |
52-Week Low | $10.68 | $7.75 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $3.55B | $3.18B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Herbalife (HLF) trades at $13.03, up 3.0% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 8.22 and P/S of 0.26, while maintaining strong gross margins of 77.7%. Recent Q1 2026 earnings beat expectations, though Q2 2026 missed. The company announced a $250 million share repurchase program and CEO transition, with management reaffirming 2026 guidance. Cash flow trends show improvement with projected positive net cash flow of $50 million for 2026.
HLF presents a value opportunity with discounted valuation and improving debt profile, though execution risks remain. Analyst consensus targets $19.00 (53.8% upside) with 14 buy ratings. Key risks include mixed earnings performance, high debt levels despite recent reduction, and leadership transition. The stock offers potential for re-rating if management delivers on margin expansion and growth targets outlined in recent investor presentations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →